Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | DPYD | Q12882 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44459 | 0.82 | GAA (0.52) | GAADPYDMAPT | |
| Water SCHEMBL11272295 | 0.80 | GAA (0.50) | GAADPYDMAPT | |
| Water SCHEMBL6482818 | 0.80 | GAA (0.50) | GAADPYDMAPT | |
| SCHEMBL28633880 | 0.77 | GAA (0.44) | GAADPYDMAPT | |
| SCHEMBL29002023 | 0.76 | GAA (0.37) | GAAMAPT | |
| Phosphoric Acid SCHEMBL29493371 | 0.75 | GAA (0.45) | GAADPYDMAPT | |
| Uracil SCHEMBL29116490 | 0.70 | CRBN (0.57) | GAAMAPT | |
| SCHEMBL7070324 | 0.68 | GAA (0.50) | GAADPYDMAPT | |
| SCHEMBL2037916 | 0.67 | DPYD (0.46) | GAADPYDMAPT | |
| SCHEMBL29266086 | 0.67 | GAA (0.37) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937812-A2 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS | Cancer Research Technology Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042554-A2 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2007-04-19 | — | — | WO | disclosed |